3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Colonic Neoplasms
5
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Motor Activity
2
Gastrointestinal Neoplasms
2
Vitamin D Deficiency
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Psychological Well-Being
1
Prostatic Neoplasms
1
Postoperative Complications
1
Pancreatic Neoplasms
1
Osteoporosis
1
Neoplasms
1
Myocardial Ischemia
1
Lung Neoplasms
1
Inflammation
1
Hypertension
1
Heart Diseases
1
Fibrosis
1
Esophageal Neoplasms
1
Coronary Disease
1
Cognitive Dysfunction
1
Cholangiocarcinoma
1
Cardiovascular Diseases
1
Breast Neoplasms
1
Bone Diseases
1
Interventions
pembrolizumab
36
Magnetic Resonance Spectroscopy
23
Gemcitabine
19
Specimen Handling
15
Nivolumab
12
Carboplatin
12
Surveys and Questionnaires
11
Paclitaxel
11
Cetuximab
11
Early Intervention, Educational
10
Bevacizumab
10
Standard of Care
9
Cyclophosphamide
9
Cisplatin
9
Radiosurgery
8
Methods
8
Fluorouracil
8
Docetaxel
8
Blood Specimen Collection
8
Psychiatric Rehabilitation
7
Pemetrexed
7
sargramostim
6
aldesleukin
6
Taxes
6
Injections
6
Fluorodeoxyglucose F18
6
Educational Status
6
Drug Therapy
6
Biopsy
6
Albumin-Bound Paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Vitamin D
×
Gastrointestinal
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled